Reported Sunday, KIMMTRAK Five-Year Phase 3 Data Shows Doubled Survival Likelihood Versus Investigator's Choice With Median OS Of 21.6 Months Versus 16.9 Months In Metastatic Uveal Melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease
This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor
Login to comment